Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Feb

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma

Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers

CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax

Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy